Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:OCUL), noting the company’s lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular ...
Medical Xpress on MSN13d
Innovative treatment method offers hope for treating wet AMDAge-related macular (AMD) degeneration is a leading cause of vision impairment and blindness in the elderly population.
The cause of age-related macular degeneration can be varied and symptoms are often not recognized immediately, according to ...
New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...
Right now, the IND-enabling studies are made to test the safety, tolerability, vector biodistribution, transgene expression, ...
Ocular Therapeutix's Axpaxli targets wet AMD with long-acting treatment. Click here to find out why OCUL stock is a Strong ...
Dry AMD causes diminished vision accompanied by loss of central retinal pigmented epithelium (RPE) cells in individuals aged 55 and older. There are no approved vision-improving treatments for dry ...
"This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bwcc18604 ...
Zervimesine is an investigational oral, once-daily pill being developed for the treatment of CNS diseases, including ...
Delicious it might be, but healthy it is not. According to Medical News Today, foods that are high cholesterol have been ...
Baseline angiographic lesion characteristics predictive of clinical responsePublished in peer-reviewed journal Ophthalmic Surgery, Lasers and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback